Most Popular
-
1
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
2
S. Korea not to attend Sado mine memorial: foreign ministry
-
3
Wealthy parents ditch Korean passports to get kids into international school
-
4
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
-
5
First snow to fall in Seoul on Wednesday
-
6
[Weekender] Korea's traditional sauce culture gains global recognition
![[Weekender] Korea's traditional sauce culture gains global recognition](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
-
7
BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
-
8
Man convicted after binge eating to avoid military service
-
9
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
10
Gyeongju blends old with new
![[Weekender] Korea's traditional sauce culture gains global recognition](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
[THE INVESTOR] Pharmaceutical firm Celltrion’s shares rose 7 percent on Oct. 18 to close at 107,000 won ($US94.9) on expectations of Israeli genetic drug firm Teva’s acquisition of the Korean firm.
In an email interview with The Investor, the Israeli firm expressed its interest in buying the Korean firm when the latter is up for sale to strengthen its biosimilar portfolio.
Related articles :
Teva doesn’t rule out Celltrion acquisition
Pfizer to launch Celltrion’s Inflectra in November
“We will continue to investigate such opportunities as we balance risks and seek complementary skills in our partners,” Yonatan Beker, director of corporate reputation at Teva, told The Investor via email on Oct. 14.
US pharmaceutical giant Pfizer said on Oct. 18 that it would begin selling a Remicade biosimilar developed by the Korean biopharma company in the US from late November.
By Kim Young-won (wone0102@heraldcorp.com)
In an email interview with The Investor, the Israeli firm expressed its interest in buying the Korean firm when the latter is up for sale to strengthen its biosimilar portfolio.
Related articles :
Teva doesn’t rule out Celltrion acquisition
Pfizer to launch Celltrion’s Inflectra in November
“We will continue to investigate such opportunities as we balance risks and seek complementary skills in our partners,” Yonatan Beker, director of corporate reputation at Teva, told The Investor via email on Oct. 14.
US pharmaceutical giant Pfizer said on Oct. 18 that it would begin selling a Remicade biosimilar developed by the Korean biopharma company in the US from late November.
By Kim Young-won (wone0102@heraldcorp.com)
![[More than APT] Residents, architects together design homes](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/24/20241124050036_0.jpg&u=)
